antibiotic news from FierceBiotech
News
Tetraphase raises $15M for antibiotic work
Massachusetts-based Tetraphase Pharmaceuticals has closed the second tranche of its $25 million Series A financing. The $15 million tranche was funded by existing investors, including Mediphase Read more...
FDA cancels meeting as hopes rise for Basilea
The FDA has canceled a scheduled advisory board meeting on Basilea's ceftobiprole antibiotic, a move that Read more...
ALS sees strong data in Phase III antibiotic trial
Advanced Life Sciences is touting data from a recent trial of its antibiotic cethromycin. The therapy produced positive data that it can fight pneumonuia effectively and safely and demonstrated an Read more...
FDA wants more data on Theravance antibiotic
The FDA outlined new information it would need from Theravance and Astellas before it can fully approve telavancin, a new antibiotic Read more...
Targanta shares start trading at a discounted price
Shares of Targanta began trading today at $10 a share, a significant discount under the $12 to $14 range it set for itself last month. That discount will cut the company's take from the IPO from a Read more...
Nektar scores $175M pact for pneumonia therapy
Nektar Therapeutics is getting $50 million up front in a $175 million licensing deal with Bayer Healthcare for the successful development of a new therapy for severe pneumonia. Nektar will deploy its Read more...
Press Release: Genzyme Announces Data from First Phase 3 Study of Tolevamer
Press Release: Genzyme Announces Data from First Phase 3 Study of Tolevamer
Read more...Press Release: Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data
Press Release: Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data
Read more...Cosmo shares buoyed by successful antibiotic data
Shares of Italy's Cosmo Pharmaceuticals were buoyed by news of positive preliminary data from a Phase II/III trial of Rifamycin for infectious diarrhea. The antibiotic hit its primary goal of the time from taking a dose to the last unformed stool. Analysts immediately leaped on the news, citing the likelihood that the company would soon take several strides forward on its development. Lehman Brothers pegged potential annual sales at $120 million.
"We believe these positive data …
Read more...MicuRx gains $10M in financing
Union City, CA-based MicuRx Pharmaceuticals has closed a $10 million round of financing. The Morningside Group led the round of investment. MicuRx discovers and develops advanced antibacterial and antifungal drugs. "MicuRx has established a strong pipeline of research projects targeting optimization of validated antibiotic classes such as protein synthesis inhibitors," Mike Gordeev, Ph.D., executive vice president and chief scientific officer of MicuRx, said in a statement. "We are …
Read more...Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets